CMAC teams up with N4 Pharma to advance RNA therapeutics
A bold new chapter in biotech innovation is unfolding at the CMAC at the University of Strathclyde as it collaborates with N4 Pharma on a new technical evaluation project. This collaboration marks a milestone in CMAC’s mission to support industry in accelerating the development of transformative medicines.
At the heart of the project is Nuvec®, N4 Pharma’s novel silica nanoparticle delivery system. Designed to improve the delivery of RNA and DNA therapeutics, Nuvec® holds promise for cancer and other diseases such as inflammatory bowel disease (IBD). With its high drug loading capacity, targeted delivery potential, and scalable manufacturing, Nuvec® is poised to reshape how next-generation therapies reach patients.
CMAC will apply its expertise and capabilities in formulation and manufacturing science to rigorously test and characterise Nuvec® formulations. This will include evaluating single and dual siRNA loading, stability studies, and benchmarking against lipid nanoparticle controls, all critical steps in validating the systems potential.
“This project demonstrates the power of translation to industry through CRO-based collaboration. By combining N4 Pharma’s innovative delivery platform with CMAC’s technical expertise, we can unlock new possibilities in RNA therapeutics and support the journey from concept to clinic.” Kenneth Smith, Senior Programme Manager at CMAC
CMAC’s scientists are a key asset in the future of medicines manufacturing. Offering access to cutting-edge equipment, expert support and a collaborative R&D environment, CMAC supports companies to de-risk and accelerate their development pipelines. This project with N4 Pharma demonstrates a key example of how academic-industry collaboration can lead to real-world impact.
Nigel Theobald, Chief Executive Officer of N4 Pharma, “Working with CMAC is a critical step in advancing our lead programme, N4 101, and ensuring our platform meets the demands of modern RNA therapy development.”
Whether you're a biotech innovator or a pharmaceutical developer, CMAC’s scientists and world class facility offers a unique opportunity to accelerate translational research. With access to equipment, expert support, and a collaborative R&D environment, CMAC is your partner in shaping the future of medicines manufacturing.
To explore partnership opportunities, technical capabilities, and upcoming programmes visit www.cmac.ac.uk or contact our team directly at cmac-national-facility@strath.ac.uk.
ABOUT CMAC
CMAC is an industry-facing research hub that bridges academia and pharma/biotech, delivering cutting-edge solutions in modern manufacturing, crystallisation science, and digital CMC. Its National Facility operates as the CRO arm of the Centre, providing end-to-end development, manufacturing, and characterisation services to accelerate translation into industrial practice.
ABOUT N4 PHARMA
N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. Its lead programme, N4 101, is a dual-targeting, orally delivered RNA therapeutic designed to improve the lives of patients with inflammatory bowel disease. Learn more at www.n4pharma.com.
